Syngene InternationalNSE:SYNGENE -2.22%82 ROA % is 8.39% as of Mar. 2026, which is 4% below its 10-year median of 8.73. GuruFocus rates NSE:SYNGENE with a GF Score™ of 82/100 and a GF Value™ of ₹767.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Syngene International ranks better than 73.95% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Syngene International's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹5,916 Mil.
Syngene International's average Total Assets over the quarter that ended in Mar. 2026 was ₹70,547 Mil. Therefore, Syngene International's annualized ROA % for the quarter that ended in Mar. 2026 was 8.39%.
The historical rank and industry rank for Syngene International's ROA % or its related term are showing as below:
NSE:SYNGENE'
s ROA % Range Over the Past 10 Years
Min: 4.57 Med: 8.73 Max: 11.2
Current: 4.66
During the past 13 years, Syngene International's highest ROA % was 11.20%. The lowest was 4.57%. And the median was 8.73%.
NSE:SYNGENE's ROA % is ranked better than 73.95% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.35
vs NSE:SYNGENE: 4.66
Syngene International (NSE:SYNGENE) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Syngene International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's ROA % distribution charts can be found below:
* The bar in red indicates where Syngene International's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Syngene International (NSE:SYNGENE) has a ROA % of 8.39% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Syngene International and its competitors. This is near median its historical median of 8.73. Over the past decade, Syngene International's ROA % has ranged from 4.57 to 11.20. According to the industry distribution chart, Syngene International ranks #56 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 26%.
Is Syngene International's ROA % too high?
Syngene International's current ROA % of 8.39% is near median its 10-year median of 8.73. Over the past 10 years, this metric has ranged from a low of 4.57 to a high of 11.20. Based on the distribution chart, Syngene International ranks #56 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Syngene International has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #56 out of 215 companies for ROA %. This puts Syngene International in the upper half of its industry. Historically, Syngene International's own ROA % has ranged from 4.57 to 11.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Syngene International and its competitors. Syngene International's current ROA % is 8.39%, which is near median its own 10-year median of 8.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹767.78, compared to a current price of ₹430.25 — trading 44% below its estimated fair value. The current ROA % is 8.39%, which is near median its 10-year median of 8.73. Syngene International's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current ROA % is 8.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹430.25 is trading 44% below its estimated GF Value™ of ₹767.78.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
ROA %: 8.39% (near median its 10-year median of 8.73)
GF Value™: ₹767.78 vs. price of ₹430.25 (44% below fair value)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
82GF Score
Get the complete analysis for NSE:SYNGENE
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
